Lion Biotechnologies Announces First Quarter 2016 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Lion Biotechnologies Announces First Quarter 2016 Financial Results

NEW YORK, NY --(Marketwired - May 09, 2016) - Lion Biotechnologies, Inc. ( NASDAQ : LBIO ), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today reported its first quarter 2016 financial results and provided a corporate update.

For the first quarter ended March 31, 2016, Lion reported research and development expenses of $4.2 million, compared to $2.4 million for the same period in 2015. The increase in research and development spending in 2016 is due, in part, to the initiation of a Phase 2 study for LN-144 and an increase in the research activities at the company's Tampa, Florida research and development facilities. General and administrative expenses remained substantially unchanged at $2.8 million for the quarter ended March 31, 2016, compared to $2.9 million for the same period in 2015.

During the first quarter of 2016, the Company consumed a net of $4.5 million of its cash on general and administrative and research and development activities. As a result, as of March 31, 2016, the Company held $99.2 million in cash and short-term investments, compared to $103.7 million as of December 31, 2015.

First Quarter 2016 Company and Pipeline Highlights

  • Pipeline Maturation with Recent IND Allowance for Second Lead Program: The Company plans to initiate a Phase 2 trial for LN-145 for the potential treatment of cervical cancer, and head and neck squamous cell carcinoma by the end of 2016 following the allowance of an investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA) in February 2016.
  • Continuing Patient Enrollment in Phase 2 Study of Lead Product Candidate LN-144: Lion is continuing to enroll patients in a Phase 2 study of LN-144 for the treatment of refractory metastatic melanoma.
  • Senior Leadership Team Expansion: The Company announced the hiring of Steven A. Fischkoff, MD, as the company's chief medical officer in February 2016 and Michael T. Lotze, MD, as chief scientific officer and vice president of research and development in March 2016.

2016 Cash Usage Expectations

During 2016, Lion anticipates investing between $30 million and $35 million in its research, development and operations, resulting in approximately $25 million to $30 million in additional spending for the remainder of 2016.

About Lion Biotechnologies, Inc.

Lion Biotechnologies is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) for the treatment of patients with refractory metastatic melanoma, and is based on a clinical Cooperative Research and Development Agreement with the National Cancer Institute. TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and Moffitt Cancer Center. For more information, please visit http://www.lionbio.com .

Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the company's future goals, its operating and financial performance, additional studies and product development, expansion of the company's research platform, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate, or if known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections. Risks and uncertainties include, but are not limited to, the company's ability to initiate a Phase 2 trial for LN-145 by the end of 2016, its ability to continue to enroll patients in the Phase 2 trial for LN-144, and the amount that will be invested in 2016 in research and development. A further list and description of these and other risks, uncertainties and other factors can be found in Lion Biotechnologies, Inc. most recent Annual Report on Form 10-K and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or www.lionbio.com . Any forward-looking statement made in this release speaks only as of the date of this release. Lion Biotechnologies, Inc. does not undertake to update any forward-looking statements as a result of new information or future events or developments.

 
Financial Information:
 
(in 000s, except per share amounts)
 
Condensed Statement of Operations
 
    For the Three Months Ended March 31,
    2016   2015
    (unaudited)   (unaudited)
                 
Revenues   $ -     $ -  
                 
Costs and expenses                
  Research and development*     4,192       2,398  
  General and administrative**     2,818       2,900  
    Total costs and expenses     7,010       5,298  
                 
Loss from operations     (7,010 )     (5,298 )
  Interest income     126       -  
Net Loss   $ (6,884 )   $ (5,298 )
                 
Net Loss Per Share, Basic and Diluted   $ (0.14 )   $ (0.14 )
                 
Weighted-Average Common Shares Outstanding, Basic and Diluted     48,548       37,679  
                 
* Includes $585 and $387, respectively, in stock-based compensation costs  
** Includes $1,194 and $1,080, respectively, in stock-based compensation costs  
           
         
    March 31, 2016   December 31, 2015
    (Unaudited)    
Cash, cash equivalents and short-term investments   $ 99,166   $ 103,700
Total assets   $ 100,768   $ 105,653
Stockholders' equity   $ 98,938   $ 104,023
             

Investor Contact: Sarah McCabe Stern Investor Relations, Inc. 212-362-1200 Media Contact: Jody LoMenzo inVentiv Health Public Relations 646-866-1721

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Visit W&H at the Greater New York Dental Meeting

Updated Category News Views 89

Why This Event Matters for Dental Professionals Stroll through any convention center halls and you can see the future unfolding right in front of you. The upcoming Greater New York Dental Meeting is no different, especially with W&H Group setting up shop. For any dental professionals out there, this is your chance to get your hands on some real-deal tech that might just...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 168

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 113

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
SiteOne Joins S&P SmallCap 600 Amid KKR's Integer Buyout

Updated Category News Views 99

Changes on the SmallCap Horizon Starting off, SiteOne Landscape Supply (NYSE: SITE) is hopping onto the S&P SmallCap 600 bandwagon. This shift activates just as the market revs up on November 19, 2026. SiteOne is stepping in as Integer Holdings Corp. (NYSE: ITGR) makes its grand exit, a move prompted by a significant acquisition by KKR & Co. Inc. (NYSE: KKR). KKR’s...

Continue Reading
Terminus Ballet: A Decade of Defying Dance Norms

Updated Category News Views 183

A Dance Company's Journey of Transformation An anniversary represents more than just a celebration; it's a reminder of the road traveled. On Jan. 30, 2027, Terminus Modern Ballet Theatre will mark its 10th anniversary, encapsulating a decade of defiance against the staid conventions binding classical ballet. This isn't just about pirouettes and pliés—it's dance with a...

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 149

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 150

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 136

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Insight Into Midland TX Real Estate Sales Timing

Updated Category News Views 46

How Fast Do Homes Move in Midland? This ain't my first rodeo predicting the real estate rollercoaster in Texas. Midland's housing market is one nifty beast—homes can either sell like hotcakes or just sit gathering dust. You got HelloNation pulling in DeLaura Gammage, a pro who knows the terrain like the back of her hand, to spell out the why and how long it'll take to...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 122

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading

Top 5 Most Recently Viewed Articles

Chuyuan Group's Transformative Journey Towards Sustainable Success

Updated Category News Views 226

Chuyuan Group's Path to Sustainability and Growth In recent years, Chuyuan Group has significantly transformed its operations, embracing high-quality development in response to the evolving regulatory landscape. As the industry landscape changes, companies like Chuyuan must adapt to remain competitive and environmentally responsible. Understanding the Shift: Old Yang and...

Continue Reading
Adani Bonds Face Downgrade Risk Amid U.S. Bribery Scandal

Updated Category News Views 355

Fitch Ratings Puts Adani Group Bonds on Negative Watch In a significant move, Fitch Ratings has placed bonds from various units of the Adani Group on a watchlist for potential downgrades. This action follows serious allegations against the conglomerate's top executives, who are facing U.S. charges related to bribery and fraud. Implications of the Watch Status Fitch's...

Continue Reading
Investigation of Arbor Realty Trust: What Investors Should Know

Updated Category News Views 81

Understanding the Investigation of Arbor Realty Trust Faruqi & Faruqi, LLP, a well-known national securities law firm, is currently looking into claims related to Arbor Realty Trust, Inc. (NYSE: ABR). Investors who have suffered losses exceeding $100,000 while investing in Arbor are encouraged to get in touch for more information and support. Who Should Reach Out to...

Continue Reading
Qualcomm's Strategic Move: Potential Intel Acquisition Talks

Updated Category News Views 185

Qualcomm's Interest in Intel's Assets Recently, Qualcomm has made headlines by showing interest in buying parts of Intel. This move seems to be a strategic effort by Qualcomm to strengthen its presence in the competitive technology market, especially within the chip manufacturing sector. Shifting Market Dynamics Intel, a leader in chip production, is currently facing...

Continue Reading
Refined Energy Corp Expands Partnership with Eagle Plains Resources

Updated Category News Views 113

Refined Energy Corp Strengthens Its Partnership Refined Energy Corp announces an important amendment to its agreement with Eagle Plains Resources Ltd. The key focus of this amendment is to enhance their collaboration on the Dufferin Project, a project located in Canada's Athabasca Basin, known for its rich mineral deposits. Details of the Amended Agreement In a recent...

Continue Reading